3 results
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company N.V.
8 May 24
Quarterly report
4:30pm
Revenue consisted of the following:
Three months ended March 31, | ||||||||
(In thousands of USD) | 2024 | 2023 | ||||||
License revenue attributed from license performance obligation | — | 5,385 | ||||||
License revenue attributed from R&D performance obligation | 1,401 | 3,244 | ||||||
Total revenue | 1,401 | 8,629 |
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company N.V.
28 Feb 24
Annual report
8:00am
Revenue consisted of the following:
Year ended December 31, | ||||||||||||
(In thousands of USD) | 2023 | 2022 | 2021 | |||||||||
License revenue attributed from license performance obligation | 5,385 | 98,613 | — | |||||||||
License revenue attributed from R&D performance obligation | 8,705 | 4,081 | — | |||||||||
Total revenue | 14,090 | 102,694 | — |
- Prev
- 1
- Next